Overview

Mulpleo is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.

The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).

Mulpleo contains the active substance lusutrombopag.

Mulpleo is available as 3 mg tablets. The medicine can only be obtained with a prescription.

Treatment with Mulpleo should start at least 8 days before the procedure and the recommended dose is 1 tablet daily for 7 days.

For more information about using Mulpleo, see the package leaflet or contact your doctor or pharmacist.

In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow. The active substance in Mulpleo, lusutrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.

In two main studies involving adults with low levels of platelets due to long-standing liver disease, Mulpleo increased platelet count before an invasive procedure and reduced the need for transfusions.

The first study, involving 96 adults, found that 79% of patients who took Mulpleo did not require a transfusion of platelets before their procedure, compared with 13% of patients who received placebo (a dummy treatment). The second study involving 215 adults found that 65% of patients who took Mulpleo did not require platelet transfusion before their procedure, compared with 29% of patients who received placebo.

Unwanted effects that occurred in studies involving patients taking Mulpleo were headache, nausea (feeling sick), portal vein thrombosis (a blockage in the blood vessel that carries blood from the intestines to the liver) and rash. Similar effects occurred in patients receiving placebo.

For more information on the side effects and restrictions of Mulpleo, see the package leaflet.

Studies have found that Mulpleo increases platelet count, thereby lowering the risk of excessive bleeding during or after an invasive procedure and reducing the need for transfusing platelets. Unwanted effects that occurred in studies are thought to result from patients’ medical condition and the nature of the invasive procedure for which Mulpleo was used.

The European Medicines Agency decided that Mulpleo’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mulpleo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mulpleo are continuously monitored. Side effects reported with Mulpleo are carefully evaluated and any necessary action taken to protect patients.

Mulpleo received a marketing authorisation valid throughout the EU on 18 February 2019.

Mulpleo : EPAR - Medicine overview

български (BG) (100.86 KB - PDF)
español (ES) (74.18 KB - PDF)
čeština (CS) (96.77 KB - PDF)
dansk (DA) (73.12 KB - PDF)
Deutsch (DE) (74.56 KB - PDF)
eesti keel (ET) (73.17 KB - PDF)
ελληνικά (EL) (107.6 KB - PDF)
français (FR) (74.35 KB - PDF)
hrvatski (HR) (92.25 KB - PDF)
italiano (IT) (73.49 KB - PDF)
latviešu valoda (LV) (95.86 KB - PDF)
lietuvių kalba (LT) (95.95 KB - PDF)
magyar (HU) (92.92 KB - PDF)
Malti (MT) (97 KB - PDF)
Nederlands (NL) (73.66 KB - PDF)
polski (PL) (97.55 KB - PDF)
português (PT) (74.15 KB - PDF)
română (RO) (94.31 KB - PDF)
slovenčina (SK) (95.54 KB - PDF)
slovenščina (SL) (89.49 KB - PDF)
Suomi (FI) (73.05 KB - PDF)
svenska (SV) (73.4 KB - PDF)

Lusutrombopag Shionogi : EPAR - Risk-management-plan summary

Product information

Mulpleo : EPAR - Product information

български (BG) (703.39 KB - PDF)
español (ES) (636.47 KB - PDF)
čeština (CS) (682.47 KB - PDF)
dansk (DA) (605.81 KB - PDF)
Deutsch (DE) (646.78 KB - PDF)
eesti keel (ET) (615.65 KB - PDF)
ελληνικά (EL) (663.32 KB - PDF)
français (FR) (660.23 KB - PDF)
hrvatski (HR) (658.33 KB - PDF)
íslenska (IS) (630.1 KB - PDF)
italiano (IT) (653.24 KB - PDF)
latviešu valoda (LV) (681.79 KB - PDF)
lietuvių kalba (LT) (648.92 KB - PDF)
magyar (HU) (649.53 KB - PDF)
Malti (MT) (638.98 KB - PDF)
Nederlands (NL) (633.99 KB - PDF)
norsk (NO) (600.15 KB - PDF)
polski (PL) (649.94 KB - PDF)
português (PT) (651.69 KB - PDF)
română (RO) (661.5 KB - PDF)
slovenčina (SK) (681.88 KB - PDF)
slovenščina (SL) (651.95 KB - PDF)
Suomi (FI) (624.01 KB - PDF)
svenska (SV) (622.71 KB - PDF)

Latest procedure affecting product information: IAIN/0017/G

05/01/2024

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Mulpleo (previously Lusutrombopag Shionogi) : EPAR - All authorised presentations

български (BG) (68.35 KB - PDF)
español (ES) (29.99 KB - PDF)
čeština (CS) (42 KB - PDF)
dansk (DA) (29.73 KB - PDF)
Deutsch (DE) (29.85 KB - PDF)
eesti keel (ET) (29.81 KB - PDF)
ελληνικά (EL) (67.71 KB - PDF)
français (FR) (29.8 KB - PDF)
hrvatski (HR) (46.05 KB - PDF)
íslenska (IS) (29.67 KB - PDF)
italiano (IT) (29.81 KB - PDF)
latviešu valoda (LV) (65.79 KB - PDF)
lietuvių kalba (LT) (61.88 KB - PDF)
magyar (HU) (66.34 KB - PDF)
Malti (MT) (65.67 KB - PDF)
Nederlands (NL) (29.74 KB - PDF)
norsk (NO) (29.76 KB - PDF)
polski (PL) (42.62 KB - PDF)
português (PT) (25.42 KB - PDF)
română (RO) (65.59 KB - PDF)
slovenčina (SK) (42.36 KB - PDF)
slovenščina (SL) (41.67 KB - PDF)
Suomi (FI) (25.18 KB - PDF)
svenska (SV) (29.7 KB - PDF)

Product details

Name of medicine
Mulpleo (previously Lusutrombopag Shionogi)
Active substance
Lusutrombopag
International non-proprietary name (INN) or common name
lusutrombopag
Therapeutic area (MeSH)
Thrombocytopenia
Anatomical therapeutic chemical (ATC) code
B02BX

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

Authorisation details

EMA product number
EMEA/H/C/004720

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Marketing authorisation holder
Shionogi B.V.

Herengracht 464
1017 CA
Amsterdam
The Netherlands

Opinion adopted
13/12/2018
Marketing authorisation issued
18/02/2019
Revision
9

Assessment history

Mulpleo : Procedural steps taken and scientific information after authorisation

Lusutrombopag Shionogi : EPAR - Public assessment report

CHMP summary of positive opinion for Lusutrombopag Shionogi

Topics

This page was last updated on

How useful do you find this page?